OncoMatch/Clinical Trials/NCT06827899
Veneclax, Chidaniline Combined With Azacitidine Followed by Decitabine + MAG Regimen in the Treatment of Elderly Untreated AML
Is NCT06827899 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies veneclax, chidaniline combined with azacitidine (VCA) followed by decitabine + MAG regimen (D-MAG) for acute myeloid leukemia.
Treatment: veneclax, chidaniline combined with azacitidine (VCA) followed by decitabine + MAG regimen (D-MAG) — A multicenter, prospective, single-arm clinical study of veneclax, chidaniline combined with azacitidine (VCA) followed by decitabine + MAG regimen (D-MAG) in the treatment of elderly untreated acute myeloid leukemia (AML)
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Excluded: BCR ABL1 translocation
AML with BCR-ABL1 translocation
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: hypomethylation agent
Participants have received the following treatments: hypomethylation agents
Cannot have received: BCL2 inhibitor (venetoclax)
Participants have received the following treatments: venetoclax
Cannot have received: chemotherapy for myelodysplastic syndrome (MDS)
Participants have received the following treatments: chemotherapy for myelodysplastic syndrome (MDS)
Lab requirements
Kidney function
Estimated creatinine clearance >= 30 mL/min
Liver function
AST and ALT <= 3.0 x ULN (unless considered due to leukemic organ involvement). Bilirubin <= 1.5 x ULN (unless considered due to leukemic organ involvement)
Cardiac function
Clinically significant QTc interval prolongation (male > 450 ms; female > 470 ms), ventricular tachycardia and atrial fibrillation, second-degree heart block, myocardial infarction, and congestive heart failure within one year before enrollment patients, and patients with coronary heart disease who have clinical symptoms and need drug treatment [excluded]
AST and ALT <= 3.0 x ULN (unless considered due to leukemic organ involvement). Bilirubin <= 1.5 x ULN (unless considered due to leukemic organ involvement); Estimated creatinine clearance >= 30 mL/min; Clinically significant QTc interval prolongation (male > 450 ms; female > 470 ms), ventricular tachycardia and atrial fibrillation, second-degree heart block, myocardial infarction, and congestive heart failure within one year before enrollment patients, and patients with coronary heart disease who have clinical symptoms and need drug treatment [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify